Addressing the challenges in enrolling oncology and rare disease trial participants

Sponsored by: Acurian

Focused on:

    Date: 15 December


    Time: London 3PM / New York 10AM

    Innovative CTL program for faster, more efficient enrollment

    Successful accrual to oncology and other rare disease clinical trials present diverse and unique challenges for study teams. We have found that to be successful, accrual strategies must shift the focus from prospective patients to the team providing healthcare, and concentrate on providing information and critical support to the treatment team, lowering historic barriers to enrollment. In oncology, the treatment team serves as either enabler or gatekeeper when clinical trials are offered as a treatment option.

    The innovative Clinical Trial Liaison (CTL) program offers support to the treatment team, and enables them to be better prepared for patient inquiries.

    Acurian provides insight into the new paradigm of enrolling oncology and rare disease studies.

    Presented by

    Edwin Watson,

    Senior Director of Oncology

    Ed Watson is responsible for Acurian's Oncology Programs, and previously at Acurian was in charge of Corporate Development, responsible for many external business relationships and supporting the continued enhancement and development of Acurian's capabilities in patient accrual in clinical trials. Watson brings 16 years experience with the pharmaceutical industry at Schering-Plough, Pharmacia and GlaxoSmithKline, where he held senior positions in marketing, pharmaceutical pricing strategy and the technical operations supporting those efforts.

    Download Slides

    Please login to download the slides

    Key Learning Objectives

    • Investigating why oncology and rare diseases are different from other therapeutic areas
    • Exploring challenges of enrolling and distinguishing them from other therapeutic areas
    • Providing information and critical support to the healthcare team to lower barriers to enrollment
    • Understanding what implications to approach for improving or changing process of clinical trials


    • CEO/President/Chairman/Executive Director
    • Clinical Operations
    • Clinical Trial/Operations - VP/Director/Manager
    • Trial Site Management
    • CEO
    • VP
    • and Director level personnel in oncology focusing on clinical trials
    • clinical outsourcing
    • clinical operations.